ICICI Prudential Nifty Pharma Index Fund Direct Growth NAV today
AMFI: 150930ISIN: INF109KC11M9MUTF_IN: ICIC_PRU_NFTY_4NHDKJICICI Prudential Mutual FundIndex funds
NAV ₹20.3314up ₹0.38 (1.90%)
NAV for 27 Oct 2026, against 26 Oct 2026. Declared once a day.
Other plans: Direct IDCW ₹20.3324 · Regular Growth ₹19.8356, 1.89% · Regular IDCW ₹19.8356
- Fund sizeAssets under management. The money the fund manages for all its investors, across every plan, at the end of the month. Assets under management in the glossary
- ₹163 CrSep 2026
- Expense ratioTotal expense ratio. What the fund charges each year as a share of the money invested, taken out of the NAV every day, so the returns shown are already after it. Total expense ratio: how it is worked out
- 0.51%22 Oct 2026
- Exit loadExit load. A charge, as a share of the amount redeemed, on units sold before a set period has passed since they were bought. Exit load in the glossary
- None
- P/EP/E. What the fund pays for each rupee of yearly profit its companies earn: the total value of its shares divided by those companies' last four quarters of profit, each in proportion to what the fund holds. The profit leaves out one-off items (exceptional items and businesses sold or demerged), so one company's one-off gain cannot pull the fund's P/E down. A loss-making company lowers the profit. Shown when at least 80% of the fund's shares are counted. P/E in the glossary
- 37.030 Sep 2026
- Risk levelRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month. Riskometer in the glossary
- Very HighAug 2026
- HoldingsHoldings. The number of different securities in the fund's latest monthly portfolio: shares, bonds, money market paper and units of other funds, not cash, overnight lending or futures. Holdings in the glossary
- 2030 Sep 2026
- LaunchedLaunch date. The day the fund first allotted units to investors, at the close of its new fund offer. Launch date in the glossary
- 14 Dec 2022
ICICI Prudential Nifty Pharma Index Fund returns
Direct Growth plan
Over each window to 27 Oct 2026
| Over | Direct GrowthTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). Trailing return: how it is worked out | Regular Growth | BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back. Benchmark in the glossary |
|---|---|---|---|
| 1 week | +2.52% | +2.51% | +2.55% |
| 1 month | −2.77% | −2.83% | −2.72% |
| 3 months | +1.18% | +1.01% | +1.29% |
| 6 months | +13.48% | +13.10% | +13.76% |
| 1 year | +17.85% | +17.08% | +18.44% |
| 3 years | +21.29% | +20.53% | +22.03% |
| 5 years | Needs 5 years | – | – |
₹10,000 put in on 15 Dec 2022 is ₹20,449 at the NAV of 27 Oct 2026Growth of ₹10,000. What ₹10,000 put in at the NAV of the first day would be worth at the latest NAV, after the fund's expenses and before tax and any exit load. Growth of ₹10,000 in the glossaryOver a year and longer, a return is the yearly rate. Benchmark: Nifty Pharma TRI, over the same days as the fund.
At the month end, 30 Sep 2026
| Over | Fund | BenchmarkBenchmark return. The change in the benchmark index's total return level over the same dates as the fund's return, as a yearly rate over a year and longer. Benchmark return in the glossary |
|---|---|---|
| 1 year | +23.37% | +23.98% |
| 3 years | +19.70% | +20.43% |
| Since launch | +20.77% | +21.74% |
Benchmark: Nifty Pharma TRI. Both as the fund house states them for the month.
Return in each calendar year
- Fund, Direct GrowthCalendar year return. The change in NAV from the last NAV of one year to the last NAV of the next.
- Nifty Pharma TRI
- Loss
Highest year to Dec 2024, +38.8%; lowest year to Dec 2025, −2.6%Above the benchmark in 0 of 3 years
ICICI Prudential Nifty Pharma Index Fund SIP returns
₹10,000 on the 1st of every month, valued at the NAV of 27 Oct 2026SIP calculator
| Period | InvestedAmount invested. ₹10,000 on the 1st of every month, or the next day the fund priced, added up over the period. Amount invested in the glossary | Value todayValue today. What the units bought by every instalment are worth at the latest NAV. Value today in the glossary | Invested against value today | SIP returnSIP return (XIRR). The yearly rate that, applied to each monthly instalment from the day it was invested, gives the value of all the units today. SIP return (XIRR) in the glossary | After stamp dutySIP return after stamp duty. The same SIP return with stamp duty of 0.005% taken from every instalment since 1 Jul 2020, so ₹10,000 buys ₹9,999.50 of units. SIP return after stamp duty in the glossary | Stamp dutyStamp duty paid. The stamp duty on all the instalments, in rupees: 0.005% of each purchase made since 1 Jul 2020. Stamp duty paid in the glossary |
|---|---|---|---|---|---|---|
| 1 year12 instalments | ₹1,20,000 | ₹1,32,562₹1,32,555 after stamp duty | +20.44% | +20.43% | ₹6 | |
| 3 years36 instalments | ₹3,60,000 | ₹4,46,266₹4,46,244 after stamp duty | +14.57% | +14.57% | ₹18 | |
| Since Dec 202246 instalments | ₹4,60,000 | ₹6,45,034₹6,45,002 after stamp duty | +17.96% | +17.96% | ₹23 |
5 years: Launched 14 Dec 2022, needs 5 years of history.
A SIP that rises every year: Step-up SIP calculator
Rolling returns
Per cent a year, every window from 15 Dec 2022 to 27 Oct 2026
Lowest to highestAverage
LowestLowest rolling return. The lowest yearly return of any window of this length in the fund's history, one window starting on each day it priced. Lowest rolling return in the glossaryAverageAverage rolling return. The average of the yearly returns of every window of this length in the fund's history. Average rolling return in the glossaryHighestHighest rolling return. The highest yearly return of any window of this length in the fund's history. Highest rolling return in the glossaryEnded higherWindows that ended higher. The share of all the windows of this length in which the NAV ended above where it started. Windows that ended higher in the glossary
1 year706 windows−8.4%+23.3%+62.7%90.2%
3 yearsLaunched 14 Dec 2022, needs 4 years of history
Tracking error
Against Nifty Pharma TRI, as on 30 Sep 2026.
Against its index, by window
| Measure | Direct, this plan | Regular |
|---|---|---|
| Tracking errorTracking error. How much an index fund's daily returns differed from its index's, stated as a yearly figure. Tracking error in the glossary | 0.05% | 0.06% |
| Difference, 1 yearTracking difference. The index fund's return less its index's return over the same period; the fund's costs make it negative. Tracking difference in the glossary | −0.60 pts | −1.40 pts |
| Difference, 3 years | −0.74 pts | −1.48 pts |
| Difference since launch | −0.97 pts | −1.74 pts |
Difference: the fund's return less the index's, in percentage points.
ICICI Prudential Nifty Pharma Index Fund expense ratio and exit load
Per cent of the money invested, a year. Each month shows its last day filed; the parts were redefined from Apr 2026.
- Regular over directDirect and regular plan cost gap. The regular plan's expense ratio less the direct plan's: what buying through a distributor costs each year, since both plans own the same portfolio. Direct and regular plan cost gap in the glossary
- 0.62 ptsA year, on 22 Oct 2026
- Direct, 30-day averageExpense ratio, 30-day average. The total expense ratio averaged over the last 30 days the fund filed it, which evens out the day-to-day moves in brokerage and levies. Expense ratio, 30-day average in the glossary
- 0.51%Over the last 30 days filed
- Regular, 30-day average
- 1.18%Over the last 30 days filed
Total expense ratio, month by month
- Regular plan
- Direct plan
Direct plan highest 0.52%, Aug 2026.Direct plan lowest 0.29%, Mar 2024.
What the expense ratio is made of
| Part | Direct | Regular |
|---|---|---|
| Base expense ratioBase expense ratio. The part of the expense ratio that pays the fund house and the distributor, before brokerage, transaction costs, levies and GST. Base expense ratio in the glossary | 0.32% | 0.85% |
| Brokerage | 0.01% | 0.01% |
| Transaction costs | None | None |
| Statutory levies | 0.18% | 0.27% |
Per cent of assets a year, filed for 22 Oct 2026. The parts add up to that day's total.
Buying and selling
- Lump-sum purchases
- Accepted
- Minimum investmentMinimum investment. The smallest amount the plan accepts for a first purchase. Minimum investment in the glossary
- ₹1,000
- Minimum top-up
- ₹1,000
- Minimum redemption
- ₹1
- SIP
- Accepted
- STP, transfers to another fund
- Not accepted
- SWP, regular withdrawals
- Accepted
- Switches
- Accepted
- Lock-inLock-in. The time after each purchase during which those units cannot be sold. Lock-in in the glossary
- None
- SIP minimum
- Daily,Weekly,Fortnightly,Monthly = Rs. 1000Quarterly = Rs. 5,000
- SIP instalments, at least
- Daily,Weekly,Fortnightly,Monthly = 6Quarterly = 4
- SIP dates
- Daily = Daily (only business days)Weekly = Anyday (Monday to Friday)*Fortnightly = 1st and 16th day of each month as applicableMonthly = Any date*Quarterly = Any date**In case the date chosen for SIP falls on a Non-Business Day or on a date which is not available in a particular month, the SIP will beprocessed on the immediate next Business Day.
As listed for this plan on 27 Oct 2026.
ICICI Prudential Nifty Pharma Index Fund AUM
₹ crore, every plan of the fund together.
- Average assetsAverage assets under management. The money the fund managed, averaged over every day of the quarter, added up across its plans.
- ₹151 CrQuarter to Sep 2026
- In the direct plansShare of assets in the direct plans. The direct plans' average assets for the quarter as a percentage of the fund's total; the rest is in the regular plans, bought through distributors. Share of assets in the direct plans in the glossary
- 69.2%Of the quarter's average
Average assets by quarter, by plan
- Regular plans
- Direct plans
The latest quarter is the largest since the quarter to Jun 2022.
Assets at each month end
The latest month end is the highest since Dec 2023.Lowest ₹28 Cr, Dec 2023.
ICICI Prudential Nifty Pharma Index Fund portfolio
Portfolio disclosed for 30 Sep 2026.
Holdings on 30 Sep 2026
| Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month. Large, mid and small cap in the glossary | Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. Weight in the fund in the glossary | Held since. The first month end of the fund's current run of holding this position; marked "or earlier" where that month is the fund's first portfolio on record or the first after a gap in its portfolios. Held since in the glossary | |||
|---|---|---|---|---|---|
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | Large cap13th | 19.50% | 31.81 | 1,75,082 | Dec 2022or earlier |
| Divi's LaboratoriesPharmaceuticals & Biotechnology | Large cap50th | 11.97% | 19.52 | 21,013 | Dec 2022or earlier |
| Laurus LabsPharmaceuticals & Biotechnology | Mid cap171st | 7.82% | 12.75 | 64,400 | Dec 2022or earlier |
| CiplaPharmaceuticals & Biotechnology | Large cap99th | 7.68% | 12.52 | 93,053 | Dec 2022or earlier |
| Dr. Reddy's LaboratoriesPharmaceuticals & Biotechnology | Mid cap104th | 7.62% | 12.43 | 1,00,842 | Dec 2022or earlier |
| Torrent PharmaceuticalsPharmaceuticals & Biotechnology | Large cap61st | 7.16% | 11.68 | 24,332 | Dec 2022or earlier |
| LupinPharmaceuticals & Biotechnology | Mid cap105th | 5.00% | 8.15 | 40,165 | Dec 2022or earlier |
| Aurobindo PharmaPharmaceuticals & Biotechnology | Mid cap138th | 4.68% | 7.64 | 45,698 | Dec 2022or earlier |
| Glenmark PharmaceuticalsPharmaceuticals & Biotechnology | Mid cap176th | 3.56% | 5.81 | 24,895 | Dec 2022or earlier |
| Alkem LaboratoriesPharmaceuticals & Biotechnology | Mid cap164th | 3.16% | 5.15 | 9,970 | Dec 2022or earlier |
| Zydus LifesciencesPharmaceuticals & Biotechnology | Mid cap114th | 2.92% | 4.76 | 40,975 | Dec 2022or earlier |
| Mankind PharmaPharmaceuticals & Biotechnology | Mid cap119th | 2.88% | 4.69 | 18,737 | Mar 2024 |
| IPCA LaboratoriesPharmaceuticals & Biotechnology | Mid cap229th | 2.71% | 4.43 | 22,971 | Dec 2022or earlier |
| BioconPharmaceuticals & Biotechnology | Mid cap173rd | 2.62% | 4.27 | 1,15,240 | Dec 2022or earlier |
| Gland PharmaPharmaceuticals & Biotechnology | Small cap261st | 2.34% | 3.82 | 13,178 | Dec 2022or earlier |
Weight is per cent of the fund's net assets; value in ₹ crore.
Cash and receivables on 30 Sep 2026
| TREPS | 1.50% | 2.45 |
| Net Current Assets | −1.44% | −2.35 |
Weight is per cent of the fund's net assets; value in ₹ crore.
- Largest holdingLargest holding. The share of the fund in its single largest position, cash and futures not counted as positions. Largest holding in the glossary
- 19.50%Sun Pharmaceutical Industries
- Top 5 holdingsTop 5 holdings. The share of the fund held in its five largest positions. Top 5 holdings in the glossary
- 54.59%
- Top 10 holdingsTop 10 holdings. The share of the fund held in its ten largest positions. Top 10 holdings in the glossary
- 78.16%
- Effective holdingsEffective number of holdings. The number of equal-sized positions that would be as concentrated as the fund's actual weights. Effective number of holdings in the glossary
- 11.4Taken over 99.94% of the fund
Asset allocation
Asset allocation. What the fund owns, by kind of asset, each as a share of its net assets; futures and options are shown beside it, not in it, since they are contracts rather than assets bought. Asset allocation in the glossary- Indian shares99.94%
- Cash and receivables0.06%
Per cent of the fund's net assets.
Large, mid and small cap
- Large cap46.34%
- Mid cap46.10%
- Small cap7.56%
Per cent of the fund's Indian shares. By the list for the six months to Jun 2026.
Sector allocation
Sector weight. The fund's shares grouped by the business each company is in, less the futures sold on them, each group as a share of the fund's net assets. Sector weight in the glossary1sector
- Healthcare99.94%
Per cent of the fund's net assets, less the futures sold on its shares, Sep 2026.
Sector allocation month by month
| 13 months | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare20 companies | 99.94% | 99.93% | 99.96% | 99.94% | 99.50% | 99.94% | 99.86% | 99.35% | 100.35% | 99.95% | 99.97% | 99.98% |
Per cent of the fund's net assets, less the futures sold on its shares, at each month end, Oct 2025 to Sep 2026; the line runs from Sep 2025.
Bought and sold
Sep 2026 against Aug 2026, position by position.
Positions changed, month by month
- New
- Added
- Trimmed
- Sold out
- New positionsNew positions. Holdings in this month's portfolio that were not in the month before. New positions in the glossary
- 0
- Sold outSold out. Holdings in last month's portfolio that are gone from this one, other than a bond or deposit repaid on its due date. Sold out in the glossary
- 0
- Added toAdded to. Holdings with more units than the month before. Where the fund states no units, a weight that rose by more than a tenth. Added to in the glossary
- 20
- TrimmedTrimmed. Holdings with fewer units than the month before. Where the fund states no units, a weight that fell by more than a tenth. Trimmed in the glossary
- 0
- UnchangedUnchanged. Holdings with the same number of units as the month before. Their weight can still move with the price. Unchanged in the glossary
- 0
- Traded at leastTraded at least. The smaller of the weight bought in new positions and the weight sold out of old ones, cash left out: the least the fund must have bought and sold in the month. Traded at least in the glossary
- 0.00%
- Weight that movedWeight that moved. Half the sum of every position's change in weight between the two month ends, new and sold positions included; price moves alone raise it. Weight that moved in the glossary
- 2.28%
Changes in Sep 2026
| What changed. New: not held the month before. Added or trimmed: more or fewer units than the month before, or, where no units are stated, a weight that moved by more than a tenth. Sold out: held the month before, gone now. Matured: a bond or deposit whose repayment date fell between the two portfolios, so it was repaid rather than sold (one sold in its last days reads the same). What changed in the glossary | Change in weight. The holding's weight this month less its weight the month before, in percentage points; a price move alone changes it. Change in weight in the glossary | ||||
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | Added | 19.50% | 20.76% | −1.26 pts | +10,976 |
| Dr. Reddy's Laboratories | Added | 7.62% | 6.95% | +0.67 pts | +6,371 |
| Laurus Labs | Added | 7.82% | 7.36% | +0.46 pts | +4,108 |
| Biocon | Added | 2.62% | 2.90% | −0.29 pts | +4,670 |
| Lupin | Added | 5.00% | 5.25% | −0.25 pts | +2,534 |
| Wockhardt | Added | 1.77% | 1.54% | +0.24 pts | +871 |
| Ajanta Pharma | Added | 1.67% | 1.50% | +0.18 pts | +1,021 |
| Torrent Pharmaceuticals | Added | 7.16% | 7.34% | −0.18 pts | +1,608 |
| Mankind Pharma | Added | 2.88% | 2.70% | +0.17 pts | +1,203 |
| Cipla | Added | 7.68% | 7.83% | −0.15 pts | +5,853 |
| Sai Life Sciences | Added | 2.14% | 1.99% | +0.15 pts | +1,496 |
| Glenmark Pharmaceuticals | Added | 3.56% | 3.69% | −0.12 pts | +1,570 |
| Abbott India | Added | 1.43% | 1.31% | +0.12 pts | +66 |
| Divi's Laboratories | Added | 11.97% | 11.88% | +0.09 pts | +1,325 |
| Alkem Laboratories | Added | 3.16% | 3.08% | +0.08 pts | +914 |
Weights are per cent of the fund's net assets; a change in weight is in percentage points.
Holdings month by month
| Holding | Oct 25 | Nov 25 | Dec 25 | Jan 26 | Feb 26 | Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries | 22.18%Cut | 23.17%Cut | 22.05%Added | 21.38%Added | 21.81%Cut | 22.89%Added | 22.53%Added | 21.33%Added | 21.31%Added | 21.33%Added | 20.76%Added | 19.50%Added |
 Divi's Laboratories | 10.66%Cut | 9.87%Cut | 9.84%Added | 9.73%Added | 9.65%Cut | 9.30%Added | 9.72%Added | 9.48%Added | 9.04%Added | 10.36%Added | 11.88%Added | 11.97%Added |
 Laurus Labs | 4.61%Cut | 4.81%Cut | 5.21%Added | 4.75%Added | 4.96%Cut | 4.75%Added | 5.04%Added | 5.93%Added | 6.38%Added | 7.15%Added | 7.36%Added | 7.82%Added |
 Cipla | 10.51%Cut | 10.34%Cut | 10.30%Added | 9.43%Added | 8.99%Cut | 8.47%Added | 8.67%Added | 8.83%Added | 8.91%Added | 8.39%Added | 7.83%Added | 7.68%Added |
 Dr. Reddy's Laboratories | 9.08%Cut | 9.20%Cut | 9.38%Added | 9.40%Added | 9.29%Cut | 9.41%Added | 9.49%Added | 8.89%Added | 8.94%Added | 7.08%Added | 6.95%Added | 7.62%Added |
 Torrent Pharmaceuticals | 4.64%Cut | 4.67%Cut | 4.88%Added | 5.24%Added | 5.37%Cut | 5.43%Added | 5.15%Added | 5.16%Added | 5.24%Added | 7.60%Added | 7.34%Added | 7.16%Added |
 Lupin | 5.91%Cut | 6.05%Cut | 6.19%Added | 6.61%Added | 6.62%Cut | 6.90%Added | 6.58%Added | 6.16%Added | 6.35%Added | 5.94%Added | 5.25%Added | 5.00%Added |
 Aurobindo Pharma | 3.97%Cut | 4.12%Cut | 4.01%Added | 4.28%Added | 4.05%Cut | 4.49%Added | 4.57%Added | 4.46%Added | 4.72%Cut | 4.43%Added | 4.69%Added | 4.68%Added |
 Glenmark Pharmaceuticals | 3.55%Cut | 3.52%Cut | 3.71%Added | 3.84%Added | 3.81%Cut | 3.95%Added | 4.26%Added | 3.83%Added | 3.59%Added | 3.40%Added | 3.69%Added | 3.56%Added |
 Alkem Laboratories | 3.86%Cut | 3.84%Cut | 3.90%Added | 4.21%Added | 3.91%Cut | 3.81%Added | 3.72%Added | 3.60%Added | 3.52%Added | 3.40%Added | 3.08%Added | 3.16%Added |
 Zydus Lifesciences | 3.03%Cut | 2.83%Cut | 2.77%Added | 2.80%Added | 2.73%Cut | 2.68%Added | 2.63%Added | 3.02%Added | 3.01%Added | 2.85%Added | 2.87%Added | 2.92%Added |
 Mankind Pharma | 3.36%Cut | 3.05%Cut | 3.01%Added | 3.04%Added | 3.01%Cut | 2.79%Added | 2.99%Added | 3.01%Added | 3.12%Added | 2.83%Added | 2.70%Added | 2.88%Added |
 IPCA Laboratories | 2.20%Cut | 2.42%Cut | 2.39%Added | 2.59%Added | 2.52%Cut | 2.74%Added | 2.50%Added | 2.37%Added | 2.55%Added | 2.46%Added | 2.71%Added | 2.71%Added |
 Biocon | 2.78%Cut | 2.87%Cut | 2.86%Added | 3.31%Added | 3.30%Cut | 3.17%Added | 3.02%Added | 3.43%Added | 3.23%Added | 3.07%Added | 2.90%Added | 2.62%Added |
 Gland Pharma | 1.91%Cut | 1.68%Cut | 1.66%Added | 1.86%Added | 1.72%Cut | 1.66%Added | 1.64%Added | 2.00%Added | 2.15%Added | 2.02%Added | 2.27%Added | 2.34%Added |
Per cent of the fund's net assets at each month end, Oct 2025 to Sep 2026. Under it, the change on the fund's previous month. "After a gap" is a holding after a month with no portfolio on record, so when it was bought is not known; "Not filed" is one gone across such a gap.
Portfolio turnover, per cent of assets a year
- TurnoverPortfolio turnover. How much of the portfolio the fund bought or sold over the last year, as a share of its assets, as the fund house states it. Portfolio turnover in the glossary
Highest 32.0% in Jul 2026
Risk ratios
NAV to 27 Oct 2026
How much the NAV moves
Standard deviationStandard deviation. How far the fund's monthly returns spread around their average, stated as a yearly figure: the wider the spread, the more the NAV moves. Standard deviation in the glossary16.17%
Downside deviationDownside deviation. Standard deviation counting only the months in which the fund lost money, stated as a yearly figure. Downside deviation in the glossary8.75%
Sharpe ratioSharpe ratio. The monthly return above the 91-day Treasury bill yield, divided by its standard deviation and stated for a year: the extra return for each unit of movement in the NAV. Sharpe ratio in the glossary0.84
Sortino ratioSortino ratio. The monthly return above the 91-day Treasury bill yield, divided by how far it fell below that yield and stated for a year: the extra return for each unit of movement on the way down. Sortino ratio in the glossary1.40
Against Nifty Pharma TRI
BetaBeta. How much the fund's monthly return moved for each 1% move in its benchmark: 1 moves with it, below 1 moves less. Beta in the glossary1.00
AlphaAlpha. The yearly return the fund made beyond what its beta to the benchmark accounts for. Alpha in the glossary−0.70 pts
R-squaredR-squared. The share of the fund's monthly movement that its benchmark's movement explains, from 0 to 100. R-squared in the glossary100.0
CorrelationCorrelation. How closely the fund's monthly returns moved in step with its benchmark's, from minus 1 (always opposite) to 1 (always together). Correlation in the glossary1.00
Upside captureUpside capture. The fund's return in the months its benchmark rose, as a percentage of the benchmark's return in those months. Upside capture in the glossary98.8%
Downside captureDownside capture. The fund's return in the months its benchmark fell, as a percentage of the benchmark's fall in those months. Downside capture in the glossary101.5%
Largest falls
| Largest over | FallLargest fall. The biggest drop in NAV from a high to the low that followed, before the NAV went back above that high. Largest fall in the glossary | High on | Low on | Back at the highBack at the high. The first day the NAV closed at or above the high it had fallen from. Back at the high in the glossary |
|---|---|---|---|---|
| 1 year | −7.49% | 7 Jan 2026 | 2 Feb 2026 | 26 Feb 2026 |
| 3 years and since Dec 2022 | −16.59% | 9 Oct 2024 | 28 Feb 2025 | 6 May 2026 |
Risk level by month
| Months | Fund | BenchmarkBenchmark's risk level. The riskometer level of the fund's benchmark index for the same month, on the same six-step scale as the fund's own. Benchmark's risk level in the glossary |
|---|---|---|
| Mar 2025 to Aug 202618 months | Very High | Very HighNifty Pharma TRI |
The riskometer at each month end, the fund's and its benchmark's. A month with none on record is left out.
ICICI Prudential Nifty Pharma Index Fund managers
Managers now
| Manager | Return in the manager's time. The change in the plan's NAV from the day the manager took the fund over to the latest NAV; past a year, the yearly rate that would compound to the same change. Return in the manager's time in the glossary | Benchmark over the same days. The change in the fund's benchmark index over the same days as the manager's return, worked out the same way, with the dividends of the index's companies added back. Benchmark over the same days in the glossary | Difference from the benchmark. The fund's return in the manager's time less its benchmark's over the same days, in percentage points. Difference from the benchmark in the glossary | Portfolio changed after the handover. How much of the portfolio was different three months after the manager took over: half the sum of every holding's change in weight, with each side's holdings scaled to add up to 100 so a move into cash does not count. Portfolio changed after the handover in the glossary | Portfolio changed before the handover. The same measure over the three months before the manager took over, since portfolios change anyway. Portfolio changed before the handover in the glossary | Assets the manager runs. The latest monthly size of every fund the manager runs now, added up; a fund run with others counts in full for each of its managers, and the line under it counts only the funds they run alone. Assets the manager runs in the glossary | ||
|---|---|---|---|---|---|---|---|---|
| Nishit PatelComanage | Dec 2022 | +19.74%a year | +20.69% | −0.94 pts | – | – | 60 | ₹1,98,042 Cr |
| Ashwini BharuchaComanage | Dec 2024 | +8.38%a year | +8.84% | −0.46 pts | 2.3% | 5.2% | 50 | ₹1,81,469 Cr |
| Venus Ahuja | Nov 2025 | +14.98%over 357 days | +15.53% | −0.55 pts | 4.0% | 4.6% | 59 | ₹2,02,795 Cr |
Returns are the direct plan's growth NAV, from the day each took over to the latest NAV, beside the benchmark over the same days.
Other funds they run
| Fund | |||||
|---|---|---|---|---|---|
| ICICI Prudential Nifty 50 ETFNishit Patel | Jan 2021 | – | +9.71% | – | ₹42,735 Cr |
| ICICI Prudential BSE Sensex ETFNishit Patel | Jan 2021 | – | – | – | ₹31,610 Cr |
| ICICI Prudential Gold ETFNishit Patel | Dec 2024 | – | – | – | ₹27,615 Cr |
| ICICI Prudential Nifty 50 Index FundNishit Patel | Jan 2021 | +9.41%a year | +9.71% | −0.29 pts | ₹16,311 Cr |
| ICICI Prudential Nifty 50 ETFAshwini Bharucha | Nov 2024 | – | −1.54% | – | ₹42,735 Cr |
| ICICI Prudential BSE Sensex ETFAshwini Bharucha | Nov 2024 | – | – | – | ₹31,610 Cr |
| ICICI Prudential Gold ETFAshwini Bharucha | Nov 2025 | – | – | – | ₹27,615 Cr |
| ICICI Prudential Nifty 50 ETFVenus Ahuja | Nov 2025 | – | −10.78% | – | ₹42,735 Cr |
| ICICI Prudential BSE Sensex ETFVenus Ahuja | Nov 2025 | – | – | – | ₹31,610 Cr |
| ICICI Prudential Gold ETFVenus Ahuja | Nov 2025 | – | – | – | ₹27,615 Cr |
The ten largest by assets, by manager. Returns are the direct plan's.
Portfolio overlap
Funds holding the most of the same securities, by weight.
Closest funds in the category
Portfolios for Sep 2026. Overlap is per cent of the portfolio the two funds hold in common.
Changes to the fund
Newest first.
2026
- 1 AprExpenseExpense ratio stated under the new rules: a base ratio, with brokerage, levies and GST on top
Fund details
Objective
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
Asset allocation
- Equity and Equity related securities of companies constituting the underlying index (Nifty Pharma Index) = 95% - 100%
- Money Market instruments including TREPs* and Units of debt schemes# = 0% - 5%
Type of scheme
Open Ended
- Stated category
- Other Schemes – Index Fund
- Benchmark
- Nifty Pharma TRI
- Risk level at launch
- Very High
- New fund offer
- 25 Nov 2022 to 9 Dec 2022
- Units first allotted
- 14 Dec 2022
- Open for sale again
- 19 Dec 2022
- Price at the offer
- ₹10 a unit
- Minimum at the offer
- ₹1,000
Plans and codes
| Plan | AMFI code | ISIN | ISIN, reinvestment | MUTF_IN | First NAV |
|---|---|---|---|---|---|
| Direct Growth | 150930 | INF109KC11M9 | ICIC_PRU_NFTY_4NHDKJ | 15 Dec 2022 | |
| Regular Growth | 150929 | INF109KC18L6 | ICIC_PRU_NFTY_LAU114 | 15 Dec 2022 | |
| Direct IDCW | 150928 | INF109KC12M7 | INF109KC13M5 | ICIC_PRU_NFTY_22GFFE | 15 Dec 2022 |
| Regular IDCW | 150931 | INF109KC19L4 | INF109KC10M1 | ICIC_PRU_NFTY_14KKN9 | 15 Dec 2022 |
This fund
- Scheme information documentThe fund's objective, terms, costs and risks in full
Factsheet
- Complete Factsheet September 2026ICICI Prudential Mutual Fund, Sep 2026
- Passive Fund Factsheet September 2026ICICI Prudential Mutual Fund, Sep 2026
Statement of additional information
- SAI ICICI Prudential Mutual FundICICI Prudential Mutual Fund, Oct 2026
Annual report
- ICICI Prudential All Seasons Bond FundICICI Prudential Mutual Fund, Mar 2026
- ICICI Prudential Banking and Financial Services FundICICI Prudential Mutual Fund, Mar 2026
- ICICI Prudential Banking and PSU Debt FundICICI Prudential Mutual Fund, Mar 2026
- ICICI Prudential Balanced Advantage FundICICI Prudential Mutual Fund, Mar 2026
Riskometer disclosure
- Annual Disclosure of Scheme Riskometer FY 2025-26ICICI Prudential Mutual Fund, Mar 2026
Portfolio overlap disclosure
- Portfolio Overlap September 2026ICICI Prudential Mutual Fund, Sep 2026